Pediatrix Medical Group, Inc. MD recently teamed up with Tennessee Maternal-Fetal Medicine, a specialist group focused on high-risk pregnancies and serving patients across five locations in the Greater Nashville area. The move is aimed at expanding the maternal health services suite of MD.
Following the deal, the practice will operate as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix network.
The transaction was completed in cash and is expected to be immediately accretive to Pediatrix’s bottom line. Financial details of the transaction were kept under wraps.
The addition of new providers and clinics is expected to drive higher patient volumes and support revenue growth for MD. Its same-unit net revenue increased 4% year over year in the fourth quarter of 2025. The expansion is likely to enhance its footprint in Tennessee, supporting stronger referral networks and more consistent patient inflow.
Such targeted expansions are expected to enable MD to capture the demand for specialized maternal care. Powered by four board-certified physicians along with six practice providers, Tennessee Maternal-Fetal Medicine seems to be an apt partner to complement MD’s endeavor, as the former’s professionals focus on complex pregnancies that require specialized monitoring and treatment.
MD’s Stock Price Performance
Shares of Pediatrix have gained 48.2% over the past year against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
MD’s Zacks Rank & Key Picks
Pediatrix currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Medical space are InnovAge Holding Corp. INNV, PACS Group, Inc. PACS and GeneDx Holdings Corp. WGS, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for InnovAge Holding’s 2026 earnings is pegged at 25 cents per share, which has remained stable in the past 30 days. INNV beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 87.5%. The consensus estimate for 2026 revenues is pinned at $944.5 million, implying 10.6% year-over-year growth.
The Zacks Consensus Estimate for PACS Group’s 2026 earnings is pegged at $2.09 per share, indicating 71.3% year over year growth. PACS’s bottom line witnessed one upward revision in the past 30 days, with no movement in the opposite direction. The consensus estimate for 2026 revenues is pinned at $5.7 billion, calling for 7.7% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holding’s 2026 earnings is pegged at 75 cents per share, which has remained stable over the past 30 days. WGS beat earnings estimates in each of the trailing four quarters, with the average surprise being 164.2%. The consensus estimate for 2026 revenues is pinned at $545 million, implying 27.5% year-over-year growth.
Just Released: Zacks Top 10 Stocks for 2026
Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.
From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pediatrix Medical Group, Inc. (MD): Free Stock Analysis Report
InnovAge Holding Corp. (INNV): Free Stock Analysis Report
GeneDx Holdings Corp. (WGS): Free Stock Analysis Report
PACS Group, Inc. (PACS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).